🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are on the rise worldwide, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings published in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which uses two antibiotics. The research included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in numerous developing nations.

Clinicians treating patients have shared positive views. Having a single-dose, oral treatment of this kind is described as a "revolutionary step" for gonorrhoea control. This is deemed vital to reduce the burden of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.